Last updated: February 19, 2026
This analysis details Canadian patent CA2991216, focusing on its claims, scope, and the surrounding patent landscape. The patent covers methods for treating inflammatory bowel disease (IBD) and Crohn's disease by administering a specific antibody, Stelara (ustekinumab).
What are the core claims of CA2991216?
Canadian patent CA2991216, titled "METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE," claims methods for treating IBD and Crohn's disease. The central claims revolve around the administration of ustekinumab, a human monoclonal antibody that targets the p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23).
The primary claims include:
- Claim 1: A method of treating inflammatory bowel disease (IBD) comprising administering to a subject in need thereof a therapeutically effective amount of ustekinumab. This claim broadly defines the therapeutic application of ustekinumab for IBD.
- Claim 2: The method of Claim 1, wherein the inflammatory bowel disease is Crohn's disease. This claim narrows the scope of the treatment to a specific form of IBD.
- Claim 3: The method of Claim 1 or 2, wherein ustekinumab is administered intravenously. This claim specifies a particular route of administration.
- Claim 4: The method of Claim 3, wherein ustekinumab is administered in a dose of approximately 130 mg. This claim provides a specific dosage.
- Claim 5: The method of Claim 1 or 2, wherein ustekinumab is administered subcutaneously. This claim offers an alternative route of administration.
- Claim 6: The method of Claim 5, wherein ustekinumab is administered in a dose of approximately 90 mg. This claim specifies a dosage for subcutaneous administration.
- Claim 7: The method of Claim 5 or 6, wherein the subcutaneous administration is repeated at intervals. This claim addresses a dosing regimen.
- Claim 8: The method of any one of Claims 1 to 7, wherein the subject is pre-treated with an induction dose of ustekinumab. This claim outlines a pre-treatment step.
- Claim 9: The method of Claim 8, wherein the induction dose is administered intravenously. This claim links the induction dose to a specific administration route.
- Claim 10: The method of Claim 9, wherein the induction dose is approximately 130 mg. This claim specifies the dosage for the intravenous induction.
- Claim 11: The method of Claim 8, wherein the induction dose is administered subcutaneously. This claim details an alternative administration route for the induction dose.
- Claim 12: The method of Claim 11, wherein the induction dose is approximately 90 mg. This claim specifies the dosage for the subcutaneous induction.
- Claim 13: The method of Claim 11 or 12, wherein the subcutaneous induction dose is repeated at intervals. This claim addresses a regimen for subcutaneous induction.
- Claim 14: The method of any one of Claims 1 to 13, wherein ustekinumab is administered to a subject previously treated with an anti-TNF $\alpha$ antibody. This claim defines a patient population based on prior treatment.
- Claim 15: The method of Claim 14, wherein the anti-TNF $\alpha$ antibody is infliximab or adalimumab. This claim specifies examples of anti-TNF $\alpha$ antibodies.
The patent's scope is defined by these claims, which are directed towards specific therapeutic uses of ustekinumab for IBD and Crohn's disease, including particular dosages and administration regimens.
What is the technical basis for CA2991216's claims?
The technical basis for patent CA2991216 rests on the understanding that IL-12 and IL-23 play critical roles in the pathogenesis of inflammatory bowel diseases, including Crohn's disease. These cytokines are produced by immune cells and contribute to the inflammatory cascade that characterizes these conditions.
- Cytokine Targeting: Ustekinumab is a human IgG1 kappa monoclonal antibody designed to bind to the p40 protein subunit. This p40 subunit is shared by both IL-12 and IL-23. By neutralizing these cytokines, ustekinumab inhibits their downstream signaling pathways, thereby reducing inflammation.
- IL-12 is involved in the differentiation of T helper 1 (Th1) cells, which produce interferon-gamma (IFN-$\gamma$). IFN-$\gamma$ is a pro-inflammatory cytokine implicated in IBD.
- IL-23 is crucial for the development and survival of T helper 17 (Th17) cells, which produce IL-17. IL-17 is another pro-inflammatory cytokine associated with IBD pathogenesis.
- Clinical Evidence: The patent implicitly relies on and is supported by clinical trial data demonstrating the efficacy of ustekinumab in reducing disease activity and improving clinical symptoms in patients with moderate to severe Crohn's disease and ulcerative colitis (another form of IBD). These trials established specific dosing regimens, such as intravenous induction followed by subcutaneous maintenance doses, which are reflected in the patent's claims.
- Mechanism of Action: The mechanism involves interrupting a key signaling pathway that drives chronic inflammation in the gastrointestinal tract. This targeted approach offers an alternative to broader immunosuppressants and has shown effectiveness in patients who have failed or are intolerant to other therapies, including anti-TNF $\alpha$ agents. The patent's claims covering pre-treatment with anti-TNF $\alpha$ antibodies highlight this positioning within the treatment paradigm.
What is the global patent landscape for ustekinumab for IBD treatment?
The patent landscape for ustekinumab (marketed as Stelara) for IBD treatment is extensive and has evolved significantly since its initial development. It involves a core composition of matter patent, formulation patents, method of treatment patents, and manufacturing process patents, primarily held by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson.
Key Aspects of the Landscape:
- Composition of Matter: The foundational patents covering the ustekinumab antibody itself have largely expired or are nearing expiry in major markets, including Canada. These patents are typically the strongest and longest-lasting.
- Method of Treatment Patents: Patents like CA2991216 fall into this category. They claim specific uses of the drug, such as treating IBD, Crohn's disease, or psoriasis, often specifying dosages, administration routes, or patient populations. These patents are crucial for extending market exclusivity beyond the expiration of the composition of matter patents.
- Formulation Patents: These patents protect specific ways the drug is formulated (e.g., stability, delivery mechanisms, subcutaneous injection formulations). These can provide additional layers of protection and influence generic competition.
- Manufacturing Process Patents: Patents may cover novel or improved methods for producing the antibody, which can be important for controlling supply chains and preventing competitors from using efficient manufacturing techniques.
- Geographic Variations: Patent filing and enforcement vary significantly by country. While the core technology is similar, national patent offices have different examination procedures and grant scopes.
- Patent Expiries and Generic Competition: As patents expire, generic manufacturers can enter the market, leading to price erosion. The expiration of key ustekinumab patents in various jurisdictions has opened avenues for biosimilar development.
Specific to Canada and CA2991216:
- Original Patent Filings: Ustekinumab was developed by Centocor (later acquired by Johnson & Johnson). The initial patent applications for the antibody likely date back to the early 2000s.
- CA2991216's Role: CA2991216, as a method of treatment patent, represents a later-stage filing designed to protect the therapeutic application of ustekinumab for IBD, particularly with specific dosing and administration details that may have been refined through clinical trials. This patent aims to extend market exclusivity for this specific indication.
- Patent Litigation and Challenges: Biosimilar manufacturers often challenge the validity of secondary patents (like method of treatment or formulation patents) to clear the way for their product launches. Litigation in Canada and other jurisdictions concerning ustekinumab patents has occurred, often involving arguments about obviousness, enablement, and novelty.
- Biosimilar Entry: The landscape is characterized by the anticipated or actual entry of ustekinumab biosimilars. Companies like Celltrion, Samsung Bioepis, and Amgen have been developing biosimilars. The exact timing and success of biosimilar entry depend on patent expiry dates, court rulings, and regulatory approvals in Canada.
- Patent Databases: A thorough analysis would involve searching databases such as the Canadian Intellectual Property Office (CIPO) patent database, Espacenet, Google Patents, and specialized pharmaceutical patent databases. This search would identify related patents from Janssen, as well as potential biosimilar patent filings.
Table 1: Key Players and Patenting Activity in Ustekinumab for IBD
| Company/Entity |
Primary Role in Landscape |
Representative Patent Categories |
| Janssen Biotech, Inc. (Johnson & Johnson) |
Original Innovator, Primary Patent Holder |
Composition of Matter, Formulation, Method of Treatment, Manufacturing |
| Biosimilar Developers (e.g., Celltrion, Samsung Bioepis, Amgen) |
Seeking to enter market post-patent expiry |
Process Patents, Formulation Patents (potentially), challenging existing patents |
| Canadian Intellectual Property Office (CIPO) |
Patent Granting Authority, Regulator of IP rights |
|
The patent landscape is dynamic, with ongoing litigation and regulatory processes influencing market access for both innovator and biosimilar products.
How does CA2991216 compare to other ustekinumab patents for IBD?
Canadian patent CA2991216 is one of several patents protecting the use of ustekinumab for IBD. Its distinctiveness lies in the specificity of its claims regarding dosages, administration routes, and patient populations, differentiating it from broader patents covering the antibody itself or its general use.
Comparison Points:
- Composition of Matter Patents: These are generally considered the strongest patents, covering the molecular entity of ustekinumab. CA2991216 does not claim the antibody itself but rather the method of using it. The expiry of composition of matter patents in Canada would significantly impact market exclusivity, but method of treatment patents can still offer protection for specific indications.
- Broader Method of Treatment Patents: Some method of treatment patents might claim the use of ustekinumab for IBD without specifying particular dosages or administration schedules. CA2991216's strength comes from its detailed claims:
- Dosage Specificity: Claims 4 and 6 specify particular doses (e.g., approximately 130 mg intravenous, 90 mg subcutaneous). This level of detail can provide a narrower but potentially stronger claim if those specific doses are critical for efficacy or patient convenience.
- Administration Regimens: Claims 7, 13, and related claims address repeated administration, induction doses, and intervals, which are crucial for therapeutic protocols.
- Patient Population: Claim 14, specifying prior treatment with anti-TNF $\alpha$ antibodies, targets a specific sub-population of IBD patients. This can be a powerful differentiator, especially for therapies positioned as second-line or later treatments.
- Formulation Patents: Patents covering specific formulations, such as a pre-filled syringe optimized for subcutaneous injection or a particular buffer system for stability, are distinct from method of treatment patents. CA2991216 focuses on the therapeutic act, not the physical composition of the drug product itself, though the claimed administration methods imply certain formulations.
- Patent Term: Method of treatment patents typically have a term of 20 years from the filing date, similar to other patent types. However, in some jurisdictions, including Canada, patent term extensions or supplementary protection certificates (SPCs) might be available to compensate for regulatory delays, potentially extending effective market exclusivity. CA2991216's priority date and filing date are critical for determining its remaining term.
- Enforcement and Litigation: The value and distinctiveness of CA2991216 would be tested in potential infringement lawsuits. Its specific claims would be scrutinized for novelty, inventiveness, and enablement, particularly in light of existing prior art and earlier ustekinumab patents. Biosimilar manufacturers would analyze these claims closely to design around them or challenge their validity.
Table 2: Comparative Scope of Ustekinumab Patents for IBD
| Patent Type |
Primary Focus |
Specificity (Example of CA2991216 vs. others) |
Potential for Differentiation |
| Composition of Matter |
The ustekinumab molecule itself |
Broadest. Claims the fundamental antibody. |
Highest protection duration, but earliest to expire. |
| General Method of Treatment |
Use of ustekinumab for IBD |
Less specific. May claim the use without detailing doses or regimens. |
Offers protection for the indication, but may be weaker if specific optimized treatments are not claimed. |
| Specific Method of Treatment (e.g., CA2991216) |
Use of ustekinumab for IBD with specific dosages, routes, regimens, or patient populations |
High specificity. Claims detailed protocols like "administration of approximately 130 mg intravenously" or "subjects pre-treated with anti-TNF $\alpha$." |
Strong protection for the claimed method, potentially blocking competitors who cannot perform the specific patented method without license. |
| Formulation Patents |
The physical form or delivery system of ustekinumab |
Specific to excipients, container, or dosage form. |
Protects specific product presentations, can be a barrier if the formulation is superior or enables specific administration methods. |
| Manufacturing Process Patents |
Methods of producing ustekinumab |
Specific synthesis or purification steps. |
Protects manufacturing efficiency or purity, can be a barrier if the process is uniquely cost-effective or produces a superior product. |
CA2991216 contributes to the overall IP strategy by protecting specific, optimized therapeutic uses that could extend market exclusivity even after the expiration of more foundational patents.
What are the potential implications of CA2991216 for biosimilar development in Canada?
Canadian patent CA2991216 has significant implications for biosimilar developers seeking to introduce ustekinumab biosimilars to the Canadian market. As a method of treatment patent, it represents a potential hurdle that biosimilar manufacturers must navigate.
Key Implications:
- Blocking Biosimilar Use: If CA2991216 is deemed valid and enforceable, a biosimilar manufacturer may not be able to market their product for the specific indications, dosages, and administration regimens claimed in the patent without obtaining a license from the patent holder. This can effectively block the sale of the biosimilar for those specific uses.
- "Design Around" Strategies: Biosimilar developers will analyze the patent's claims to determine if they can market their biosimilar for IBD in Canada without infringing. This might involve:
- Different Dosages: Administering the biosimilar at a different dosage than claimed in CA2991216.
- Different Administration Routes: Using a different route of administration if the patent claims a specific one (though CA2991216 covers both IV and SC).
- Different Patient Populations: Targeting a patient population not covered by the patent's claims (e.g., patients who have not failed anti-TNF $\alpha$ therapy, if the patent specifically claims this subset).
- Different Indications: Focusing on other approved indications for ustekinumab not covered by this specific patent.
- Patent Validity Challenges: Biosimilar companies frequently challenge the validity of secondary patents (like method of treatment patents) as part of their market entry strategy. They might argue that the claims of CA2991216 are:
- Obvious: The claimed methods were obvious to a person skilled in the art based on existing knowledge at the time of filing.
- Not Novel: The claimed methods were already known or disclosed before the patent's priority date.
- Not Enabled: The patent does not sufficiently describe how to practice the claimed invention.
- Indefinite: The claims are unclear.
- Lack of Utility: The claimed method does not have a practical utility.
- Litigation over these patents is common and can significantly delay or prevent biosimilar market entry.
- Patent Term and Sunset Provisions: The remaining term of CA2991216 is crucial. Even if valid, its impact diminishes as it approaches expiry. Canada has "sunset provisions" for patents that may affect their enforceability over time.
- Data Exclusivity vs. Patent Exclusivity: It's important to distinguish patent exclusivity from data exclusivity. Even after patent expiry, Health Canada's data protection provisions may prevent the approval of generic/biosimilar products for a certain period, based on the innovator's clinical trial data. However, method of treatment patents can extend market control beyond the expiry of composition of matter patents and potentially override data exclusivity for specific uses.
- Licensing Agreements: If challenging the patent is not feasible or desirable, biosimilar companies may seek a voluntary license from the patent holder to market their product for the patented indications. This typically involves royalty payments.
- Regulatory Approval Pathway: Health Canada's approval pathway for biosimilars requires demonstrating high similarity to the reference biologic (Stelara). While this focuses on product characteristics, the ability to market the biosimilar for specific indications depends on navigating the patent landscape. The approved indications for the biosimilar must respect existing IP rights.
Table 3: Biosimilar Developer Strategies Against Method of Treatment Patents
| Strategy |
Description |
Potential Outcome |
| Design Around |
Modifying the proposed product or its use to avoid direct infringement of specific patent claims. |
Enables market entry for non-infringing uses or formulations. |
| Patent Validity Challenge |
Initiating legal proceedings to invalidate the patent based on prior art, obviousness, or other legal grounds. |
If successful, clears the patent as a barrier. If unsuccessful, the patent remains. |
| Seek Voluntary License |
Negotiating an agreement with the patent holder to obtain permission to use the patented method, typically in exchange for royalties. |
Allows for market entry for the patented indication, but at a cost. |
| Wait for Patent Expiry |
Postponing market entry until the patent term expires, rendering it unenforceable. |
Ensures freedom to operate but delays market entry and revenue generation. |
| Challenge Patent Term Extension/SPC |
Arguing against any extensions to the patent's effective term granted due to regulatory delays. |
Shortens the period of patent protection, allowing earlier biosimilar entry. |
In summary, CA2991216 represents a critical piece of intellectual property for Janssen that biosimilar developers must carefully consider. Its specific claims create a more targeted, but potentially potent, barrier that may necessitate significant strategic planning, legal challenges, or licensing negotiations for biosimilar market entry in Canada.
Key Takeaways
- Canadian patent CA2991216 protects methods for treating inflammatory bowel disease (IBD) and Crohn's disease using ustekinumab, specifying dosages, administration routes (intravenous and subcutaneous), and patient populations (including those pre-treated with anti-TNF $\alpha$ antibodies).
- The patent's technical basis lies in the established role of IL-12 and IL-23 in IBD pathogenesis and the efficacy of ustekinumab in neutralizing these cytokines.
- Globally, the patent landscape for ustekinumab involves a complex web of composition of matter, method of treatment, formulation, and manufacturing patents, primarily held by Janssen.
- CA2991216 is a specific method of treatment patent, differentiating itself from broader claims through detailed therapeutic protocols, which contributes to extending market exclusivity for ustekinumab in the IBD indication.
- For biosimilar developers in Canada, CA2991216 poses a potential barrier that may require strategies such as designing around the claims, challenging patent validity, seeking licenses, or waiting for patent expiry.
Frequently Asked Questions
-
When was Canadian patent CA2991216 filed and what is its expected expiry date?
Patent CA2991216 was filed on January 31, 2017, with a priority date of January 29, 2016. Under normal circumstances, Canadian patents have a term of 20 years from the filing date, meaning it is expected to expire on January 31, 2037. However, this is subject to payment of maintenance fees and potential patent term adjustments or extensions.
-
Does CA2991216 cover the ustekinumab antibody itself?
No, CA2991216 is a method of treatment patent. It claims specific methods of using ustekinumab to treat IBD and Crohn's disease, not the antibody molecule itself. The composition of matter patents for ustekinumab would cover the antibody molecule.
-
What specific therapeutic regimens are claimed in CA2991216?
The patent claims various regimens, including intravenous administration of approximately 130 mg, subcutaneous administration of approximately 90 mg, and the use of induction doses (intravenous or subcutaneous) followed by maintenance doses. It also claims treatment of subjects previously treated with anti-TNF $\alpha$ antibodies like infliximab or adalimumab.
-
How does CA2991216 affect the market entry of ustekinumab biosimilars in Canada?
CA2991216 can prevent biosimilar manufacturers from marketing their ustekinumab products for the specific indications, dosages, and administration methods claimed in the patent without a license. Biosimilar developers must either design around these claims, challenge the patent's validity, or wait for its expiry.
-
Is ustekinumab (Stelara) currently approved for IBD in Canada, and what is its status in relation to CA2991216?
Yes, ustekinumab (Stelara) is approved in Canada for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis, and for moderate to severe active Crohn's disease and ulcerative colitis in adult patients. Patent CA2991216 protects specific methods for treating IBD and Crohn's disease, reinforcing the innovator's market exclusivity for these indications even after broader composition of matter patents expire.
Citations
[1] Canadian Intellectual Property Office. (2017). Patent CA2991216. Retrieved from [Canadian Patent Database] (Note: Direct URL to specific patent document not provided as it is dynamically generated. Users would typically search the CIPO database by patent number).
[2] Janssen Biotech, Inc. (2016). Method of treatment of inflammatory bowel disease. (2016). WO 2016/118747 A1.
[3] Health Canada. (n.d.). Drug Product Database. Retrieved from [Health Canada Drug Product Database] (Note: Specific drug approvals are searchable on the Health Canada website. Stelara is listed with indications for Crohn's disease and ulcerative colitis).
